All In Biotech

Drug Trial Radar · NCT06247046

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Last checked: Nov 20, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,298 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,298

Planned (sponsor's estimate)

Start

Mar 16, 2024

Primary completion

Apr 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Live SK08 Powder compared with placebo in the treatment of participants with irritable bowel syndrome with diarrhea.

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

  • Live SK08 powderDrug

    Oral Powder

  • PlaceboDrug

    Oral Powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Who Were Composite Weekly RespondersTime frame: 1-12 weeks
  2. Adverse events and serious adverse eventsTime frame: 1-52weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China · Recruiting

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.